Minicircle DNA Vector for Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges with viral vector toxicity, immune responses, and inefficient delivery and targeting, particularly with non-viral vectors like plasmid DNA, which are susceptible to degradation and immune silencing, limiting their therapeutic potential.
Innovation Solution
Development of minivectors that are small, circular, and devoid of bacterial sequences, capable of encoding shRNA, miRNA, or genes, and can be bound by cellular components, allowing for stable transfection and persistent expression without immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If plasmid DNA vectors are used for gene therapy, then they are simple to produce and store, but they contain bacterial DNA sequences that trigger immunotoxic responses and are susceptible to degradation
Solution Approach 1:
The invention extracts and removes the harmful bacterial DNA sequences (origin of replication and antibiotic resistance gene) from the plasmid vector, retaining only the essential eukaryotic expression cassette. This creates a minicircle vector that maintains ease of production through bacterial propagation while eliminating the immunotoxic components that trigger immune responses.
Solution Approach 2:
The invention changes the structural parameters of the DNA vector by reducing its size and removing specific bacterial sequences. The minicircle vector contains only the necessary eukaryotic expression elements, fundamentally altering the vector's composition to eliminate harmful bacterial components while preserving therapeutic function.
2Quantity of substance
If large plasmid vectors are used, then they can carry sufficient genetic material, but they are susceptible to hydrodynamic shearing forces and degrade in the bloodstream
Solution Approach 1:
The invention segments the plasmid vector into essential and non-essential components, retaining only the critical eukaryotic expression cassette while removing bacterial sequences. This creates a compact minicircle vector that is resistant to hydrodynamic shearing forces while maintaining sufficient capacity for therapeutic gene expression.
Solution Approach 2:
The invention changes the physical parameter of vector size by eliminating unnecessary bacterial DNA sequences. The resulting minicircle vector has reduced molecular weight and compact structure, making it resistant to degradation by hydrodynamic shearing forces in the bloodstream while preserving therapeutic functionality.
3Ease of operation
If linear DNA vectors are used, then they are more easily introduced into cells, but they trigger rapid degradation and apoptosis due to DNA ends signaling repair pathways
Solution Approach 1:
The invention uses a circular DNA structure (minicircle vector) instead of linear DNA. The circular topology eliminates free ends that would otherwise trigger cellular DNA repair pathways and apoptosis. The closed circular structure provides stability while maintaining efficient cellular uptake and persistent gene expression.
4Productivity
If viral vectors are used, then delivery efficiency is high, but they cause toxicity, immune responses, and have limited therapeutic potential due to integration concerns
Solution Approach 1:
The invention extracts the essential function of high-efficiency gene delivery from viral vectors while removing the harmful viral components that cause toxicity and immune responses. The resulting non-viral minicircle vector achieves comparable delivery efficiency through optimized circular DNA structure without the safety concerns of viral integration and immunogenicity.
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention relates to nucleic acid molecule compositions comprising minivectors encoding a nucleic acid sequence and methods of gene therapy using minivectors encoding a nucleic acid sequence.